Plasma fibronectin in acute leukaemias and during streptokinase therapy
Bykowska, K.; Janczarski, M.; Wegrzynowicz, Z.; Lopaciuk, S.; Kopeć, M.
Materia Medica Polona. Polish Journal of Medicine and Pharmacy 20(2): 114-118
1988
ISSN/ISBN: 0025-5246 PMID: 3221728 Document Number: 314112
We have previously shown that digestion of fibronectin (FN) by trypsin, kallikrein and plasmin influences strongly the FN quantitation by electroimmunoassay (EIA) and immunoturbidimetric assay (ITA). Proteolytic degradation led to an overestimation of FN by EIA but to a decline of results in ITA. In this study, plasma FN was determined in parallel by EIA and ITA in adult patients with acute leukaemia prior to chemotherapy and in patients treated with streptokinase for deep-vein thrombosis. It has been assumed that in leukemias leukocytic proteases can degrade FN. In control persons, mean values of plasma FN determined by EIA and ITA did not differ. In contrast, significantly higher values were found by EIA than by ITA in patients with acute myeloid leukaemia (AML) and blast crsis (BC) in chronic granulocytic leukemia. A decrease in plasma FN when compared with controls was detected only by ITA but not by EIA in AML and BC. Discrepant were also results of parallel FN determination by EIA and ITA in patients treated with streptokinase. We have not confirmed recent reports on a frequent occurrence in acute leukaemia of an abnormal form of FN migrating slowly as a second peak in two-dimensional crossed immunoelectrophoresis of plasma.